Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study
Journal article
HERRINGTON W. et al, (2022), Clinical Journal of the American Society of Nephrology
Empagliflozin in Patients with Chronic Kidney Disease
Journal article
HERRINGTON W. et al, (2022), New England Journal of Medicine
Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials
Journal article
HERRINGTON W. et al, (2022), The Lancet
Estimating individual lifetime risk of incident cardiovascular events in adults with type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2)
Journal article
Bleken Østergaard H. et al, (2022), European Journal of Preventive Cardiology
Adiposity and NMR-measured lipids, lipoproteins, and metabolic biomarkers among 30,000 Mexican adults
Journal article
EMBERSON J. et al, (2022), Communications Medicine
Bioimpedance in CKD: an Untapped Resource?
Journal article
HERRINGTON W. and Mayne K., (2022), Nephrology Dialysis Transplantation
Determining the Relationship between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights from Genetic Epidemiology
Journal article
HERRINGTON W. et al, (2022), Hypertension
Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review
Journal article
Mayne K. et al, (2022), Journal of Cardiac Failure
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Journal article
LANDRAY M. et al, (2022), The Lancet
Body mass index and COVID-19 mortality: prospective study of 120,000 Mexican adults
Journal article
EMBERSON J. et al, (2022), International Journal of Epidemiology
In CKD, the Kidney Failure Risk Equation predicted 2-y risk for ESKD better than eGFR alone.
Journal article
Aguilar-Ramirez D. and Herrington WG., (2022), Ann Intern Med
In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes
Journal article
Mayne KJ. and Herrington WG., (2022), Annals of internal medicine, 175
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Journal article
HERRINGTON W., (2022), Nephrology, Dialysis and Transplantation
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
LANDRAY M. et al, (2021), The Lancet
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
Journal article
HPS3/TIMI55-REVEAL Collaborative Group Writing Committee: None. et al, (2021), Eur Heart J
Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial–Adjudicated Direct Follow-up Data in the UK
Journal article
HARPER C. et al, (2021), JAMA Network Open
Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial.
Journal article
Harper C. et al, (2021), JAMA Netw Open, 4
Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
Journal article
Staplin N. et al, (2021), EClinicalMedicine, 41, 101163 - 101163
Acute treatment effects on GFR in randomized clinical trials of kidney disease progression
Journal article
HERRINGTON W., (2021), Journal of the American Society of Nephrology
Association of kidney function with NMR-quantified lipids, lipoproteins, and metabolic measures in Mexican adults
Journal article
Aguilar-Ramirez D. et al, (2021), Journal of Clinical Endocrinology and Metabolism